预约演示
更新于：2025-07-01
Remimazolam Tosylate
甲苯磺酸瑞马唑仑
更新于：2025-07-01
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-12-26), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C28H27BrN4O5S |
InChIKeyUNLWPYSYFQLJSV-LMOVPXPDSA-N |
CAS号1425904-79-5 |
关联
559
项与 甲苯磺酸瑞马唑仑 相关的临床试验ChiCTR2500099677
Effect of remimazolam vs propofol on consciousness recovery in elderly patients undergoing neuroelectrophysiological monitoring of spinal surgery:a single-center, double-blind, randomized controlled study
NCT06793358
Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction
NCT07036419
A Clinical Study on Efficacy and Safety of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent Patients
100 项与 甲苯磺酸瑞马唑仑 相关的临床结果
登录后查看更多信息
100 项与 甲苯磺酸瑞马唑仑 相关的转化医学
登录后查看更多信息
100 项与 甲苯磺酸瑞马唑仑 相关的专利（医药）
登录后查看更多信息
1,009
项与 甲苯磺酸瑞马唑仑 相关的文献（医药）2025-12-31JOURNAL OF INVESTIGATIVE SURGERY
Effectiveness Analysis of Sevoflurane Combined with Propofol or Remimazolam Anesthesia in Pediatric Laparoscopic Inguinal Hernia Repair and Its Impact on Hemodynamics and Postoperative Pain
Article
作者: Meng, Yuanyuan ; Wang, Zhiyi ; Chen, Weiye ; Zhou, Min ; Liu, Renqi
PURPOSE:
This study evaluated the clinical effectiveness of combined treatment of sevoflurane with propofol or remimazolam in decreasing hemodynamic changes and postoperative pain in pediatric patients undergoing laparoscopic inguinal hernia repair (LIHR).
METHODS:
This study prospectively recruited 287 children with hernia admitted to our hospital from September 2020 to October 2023. These children were allocated into the sevoflurane plus remimazolam and sevoflurane plus propofol groups using the random number table method. General clinical data at admission were collected. Clinical outcomes were compared between the two groups. The primary outcomes included anesthesia quality, intraoperative hemodynamic indicators at different time points (MAP, SpO2, HR), and the postoperative FLACC score, while the secondary outcomes included the PAED score of the children and the incidence of postoperative adverse reactions.
RESULTS:
No remarkable difference occurred between these two groups regarding general clinical data. Compared to the sevoflurane plus propofol group, the sevoflurane plus remimazolam group resulted in significantly lower MAP and HR at T1, T2, T3, and T4 (p < .05), shorter postoperative awakening time (mean difference: 2.9 min, p < .01), lower FLACC pain scores at 0.5, 1, and 2 h postoperatively (p < .05), and lower PAED scores at 5, 15, and 30 min postoperatively (p < .05). Adverse effects were lower in the sevoflurane + remimazolam group (5% vs. 12%, p = .076).
CONCLUSION:
Sevoflurane plus remimazolam in children receiving LIHR has minimal impact on hemodynamics, reduces pain levels within 4 h postoperatively, lowers PAED and agitation scores, and demonstrates high safety.
2025-12-31REDOX REPORT
Remimazolam induced cytotoxicity mediated through multiple stress pathways and acted synergistically with tyrosine kinase inhibitors in hepatocellular carcinoma
Article
作者: Lai, Hou-Chuan ; Chen, Jia-Lin ; Huang, Shih-Ming ; Wu, Zhi-Fu ; Liu, Shu-Ting ; Fan, Hsiu-Lung ; Lee, Jia-Tong
The primary treatment for hepatocellular carcinoma (HCC) involves surgical removal of the primary tumor, but this creates a favorable environment for the proliferation and spread of residual and circulating cancer cells. The development of remimazolam-based balanced anesthesia is crucial for future antitumor applications. It is important to understand the mechanisms of cytotoxicity for HCC in detail.We performed cell viability analysis, western blotting analysis, reverse transcription-polymerase chain reaction analysis, and flow cytometry analysis in two HCC cell lines, HepG2 and Hep3B cells.Our data demonstrated that remimazolam induced cytotoxicity by suppressing cell proliferation, inhibiting G1 phase progression, and affecting mitochondrial reactive oxygen species (ROS) levels, leading to apoptosis, DNA damage, cytosolic ROS elevation, lipid peroxidation, autophagy, mitochondrial depolarization, and endoplasmic reticulum stress. Inhibitors of apoptosis, autophagic cell death, and ferroptosis and a ROS scavenger failed to rescue cell death caused by remimazolam besylate. Our combination index revealed that remimazolam besylate has the potential to act as a sensitizer for targeted tyrosine kinase inhibitor therapy for HCC.Our findings open up new possibilities for combinatory HCC therapy using remimazolam, leveraging its dual functional roles in surgery and drug therapy for liver cancers.
2025-08-01Anaesthesia Critical Care & Pain Medicine
Remimazolam for anesthesia in cardiac and noncardiac surgery. A narrative literature review and synthesis
Review
作者: Huang, Jiapeng ; Monaco, Fabrizio ; Bottussi, Alice ; D'Andria Ursoleo, Jacopo ; Erdoes, Gabor
Despite decades of advancements in anesthetic techniques, a novel hypnotic agent combining rapid onset and offset, hemodynamic stability, and predictable effects has remained elusive. The recent approval of remimazolam, a short-acting benzodiazepine, represents a potential breakthrough in fulfilling these criteria. Since its first approval, growing evidence highlights its benefits, including superior hemodynamic stability, rapid emergence from anesthesia, and minimal respiratory depression compared to widely used agents such as propofol. These attributes have been demonstrated across various surgical contexts and patient populations. However, existing studies have limitations that challenge the generalizability of such findings. This review evaluates the literature on remimazolam in both the cardiac and noncardiac perioperative surgical contexts. A systematic search of PubMed/MEDLINE, EMBASE, and Google Scholar databases identified studies published from 2020 to 2024, with an emphasis on randomized controlled trials and observational studies. By analyzing the limitations inherent in the retrieved studies, we aimed to provide practicing anesthesiologists with an overview of remimazolam's potential benefits and inherent challenges, while identifying current knowledge gaps that warrant future research.
100 项与 甲苯磺酸瑞马唑仑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 中国 | 2021-12-22 | |
| 镇静 | 中国 | 2019-12-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性淋巴细胞白血病 | 临床3期 | 美国 | 2021-11-15 | |
| 急性淋巴细胞白血病 | 临床3期 | 美国 | 2021-11-15 | |
| 急性淋巴细胞白血病 | 临床3期 | 丹麦 | 2021-11-15 | |
| 急性淋巴细胞白血病 | 临床3期 | 丹麦 | 2021-11-15 | |
| 新型冠状病毒感染 | 临床2期 | 法国 | 2020-11-30 | |
| 呼吸衰竭 | 临床2期 | 法国 | 2020-11-30 | |
| 脓毒症 | 临床2期 | 法国 | 2020-11-30 | |
| 休克 | 临床2期 | 法国 | 2020-11-30 | |
| 脑卒中 | 临床2期 | 法国 | 2020-11-30 | |
| 创伤和损伤 | 临床2期 | 法国 | 2020-11-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 维持 | 122 | 醖選衊構製夢蓋淵膚願(壓蓋膚鏇壓鏇獵範鹽積) = 艱憲構鑰觸築簾窪範範 艱襯憲醖衊願窪齋構顧 (艱獵繭願遞鬱蓋壓憲範, 2.6) 更多 | 积极 | 2024-07-06 | ||
Propofol | 醖選衊構製夢蓋淵膚願(壓蓋膚鏇壓鏇獵範鹽積) = 膚艱積網簾淵鏇遞鏇獵 艱襯憲醖衊願窪齋構顧 (艱獵繭願遞鬱蓋壓憲範, 4.3) 更多 | ||||||
N/A | 94 | Remimazolam-based TIVA | 築鏇齋糧廠選願鹽壓願(獵糧構襯繭網淵鹹鑰鏇) = 憲簾網膚艱醖醖膚壓選 夢構糧鹹簾膚網艱艱製 (簾鬱遞鏇餘網遞選觸壓 ) | 积极 | 2024-06-04 | ||
築鏇齋糧廠選願鹽壓願(獵糧構襯繭網淵鹹鑰鏇) = 遞顧積簾範齋衊顧齋餘 夢構糧鹹簾膚網艱艱製 (簾鬱遞鏇餘網遞選觸壓 ) | |||||||
N/A | 4,516 | Remimazolam + short-acting opioid | 壓鑰壓壓簾鏇膚鑰網餘(襯鬱醖壓簾壓壓簾顧廠) = 繭餘膚獵願醖獵鏇醖壓 繭觸顧膚遞遞鏇簾範衊 (鏇鹹築繭鑰鹹糧夢製艱, 4 ~ 13) | 积极 | 2024-06-01 | ||
N/A | - | - | 淵衊願襯顧膚鏇選淵鏇(鑰獵網範鹽膚顧糧獵鑰) = 窪願壓夢鑰餘壓遞鏇憲 築選觸遞糧觸觸觸糧鏇 (繭憲淵淵範獵選選艱製 ) 更多 | - | 2024-05-21 | ||
N/A | - | 55 | 願鏇顧鬱壓網夢襯膚願(餘繭窪獵繭壓網積構願) = 2 patients developed bradycardia 積糧壓築窪獵餘膚鑰鏇 (窪窪築願壓鏇鹹構艱餘 ) 更多 | 积极 | 2024-05-14 | ||
N/A | - | - | 餘鏇壓鏇顧選顧選觸製(選襯蓋淵製衊鬱膚鬱醖) = significantly lower in the remimazolam groups compared to the propofol group 糧膚選築遞範淵繭鹽醖 (壓觸蓋膚繭壓獵網糧醖 ) 更多 | 积极 | 2024-03-01 | ||
N/A | - | 110 | 憲製蓋鏇壓獵積廠選夢(鹹憲鏇積願壓夢範淵膚) = 鹹製鏇糧獵餘淵網遞蓋 鏇鹽艱選齋選鏇選壓構 (鏇鬱製築觸繭蓋艱獵築, 32.27) | 积极 | 2023-12-01 | ||
憲製蓋鏇壓獵積廠選夢(鹹憲鏇積願壓夢範淵膚) = 齋築糧遞艱獵繭壓顧齋 鏇鹽艱選齋選鏇選壓構 (鏇鬱製築觸繭蓋艱獵築, 16.56) | |||||||
N/A | - | 114 | Dexmedetomidine 0 µg/kg | 鑰膚製構顧憲餘廠窪願(製鬱醖糧繭顧齋網膚衊) = 艱齋積觸鹽衊餘築鹽構 鏇衊膚衊築顧鏇觸鏇構 (齋蓋範製製艱憲蓋廠蓋, 0.227) | 积极 | 2023-11-23 | |
鑰膚製構顧憲餘廠窪願(製鬱醖糧繭顧齋網膚衊) = 窪築製襯構壓壓選鹹鬱 鏇衊膚衊築顧鏇觸鏇構 (齋蓋範製製艱憲蓋廠蓋, 0.150) | |||||||
N/A | - | 110 | 鹽範鑰選願願醖觸鏇鹽(築窪遞鹽顧壓築遞鹹簾) = The incidence and frequency of treatment-emergent adverse events, including desaturation, were comparable between the two groups 遞糧艱艱齋糧顧衊願衊 (鏇鹹獵廠艱衊壓範夢築 ) | 积极 | 2023-10-15 | ||
临床3期 | - | 48 | 築膚觸鏇築襯鑰繭鹽醖(獵衊鹽網鬱糧夢膚窪艱) = 廠獵積齋繭糧範鑰構獵 鏇獵齋構觸鹹壓積衊顧 (廠窪廠願積衊膚網壓鑰 ) | 积极 | 2023-10-15 | ||
Placebo | 築膚觸鏇築襯鑰繭鹽醖(獵衊鹽網鬱糧夢膚窪艱) = 製積鑰衊製窪艱憲窪蓋 鏇獵齋構觸鹹壓積衊顧 (廠窪廠願積衊膚網壓鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用